Financing to Support Clinical Publications, Reimbursement Initiatives and Research and Development SAN MATEO, Calif. (May 6, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced...
Positive six-month results were maintained a year after TIF procedure; all control patients crossed over to receive TIF procedure and achieved similar results to original treatment group Data Presented at DDW® 2014 CHICAGO (May 5, 2014)—EndoGastric Solutions® (EGS), a...
Baldino brings nearly three decades of healthcare leadership experience to EGS as it works to advance the field of advanced endoluminal procedural techniques SAN MATEO, Calif. (May 1, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive...
Data Shows TIF Procedure Controls Subjective Parameters Better Than Maximum Dose PPI Therapy While Achieving Similar Objective Results SAN MATEO, Calif. (April 22, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for...